Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 , a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
